TECAR Therapy Device (TC2000, TC2001)
Shenzhen Dongdixin Technology Co., Ltd. · Decision date Oct 13, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K252288, the TECAR Therapy Device (TC2000, TC2001), on 2026-10-13, with the application received 07/23/2025. The applicant is Shenzhen Dongdixin Technology Co., Ltd. of Shenzhen, China. The submission is a Traditional 510(k) under regulation 878.4400, product code PBX, in the General & Plastic Surgery panel and specialty; the classification name shown is Massager, Vacuum, Radio Frequency Induced Heat. SESE means 510(k) clearance, not PMA approval.
The record shows no third-party review, no combination product status and no authorized Predetermined Change Control Plan. The listed summary is a Statement rather than a Summary. The source does not describe the device's components, technical specifications, intended use, indications, or the predicate device and comparison basis, so the scope of the clearance cannot be characterized beyond the fields above. No clinical or performance data are available in the provided material.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Oct 13, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K252288
- Regulatory pathway
- 510(k) premarket notification
- Product code
- PBX
- Decision code
- SESE
- Decision date
- Oct 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Massager, Vacuum, Radio Frequency Induced Heat.
- Product code
- PBX
- FDA device class
- 2
FDA decision timeline
K252288 received
Application receipt date recorded by FDA.
K252288 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code PBX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bh Group Us, LLC | 510(k) clearance | Sep 22, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Shenzhen Dongdixin Technology Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Shenzhen
Sources and methodology
- Original FDA record: K252288
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records